Exabis Library
Welcome to the e-CCO Library!
P432: Patient perspectives on biosimilars: a European Federation of Crohn’s and Colitis Associations survey
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P432: Patient satisfaction and patient costs associated with telephone clinic appointments in Inflammatory Bowel Disease (IBD) following the pandemic
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P432: Relationship between haemoglobin status and utility in patients with iron deficiency anaemia in inflammatory bowel disease: A post-hoc analysis of a phase 3 clinical trial
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P432: Therapeutic approaches for perianal fistula in paediatric and adolescent onset Crohn's disease – a multicentre cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P433: Aetiologies of iron deficiency-related anaemia in German patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P433: Canadian patient and caregiver perspectives on subsequent entry biologics / biosimilars for inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P433: Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P433: Faecal calprotectin is correlated to endoscopic disease activity at Week 16 in IBD patients on vedolizumab therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P433: Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P433: Postsurgical recurrence in Crohn's disease. Multicenter study in the region of Murcia, Spain of GEMEII group
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P433: Sex-based differences in response to tumor necrosis factor inhibitor induction therapy for ulcerative colitis: a pooled analysis of individual patient-level clinical trials data
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P434 Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P434: Close rectal versus total mesorectal excision in patients with inflammatory bowel disease undergoing proctocolectomy or completion proctectomy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P434: Factors associated with medical and psycosocioeconomic changes in IBD during the COVID-19 pandemic and post-pandemic period
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P434: Joint Inflammatory Bowel Disease–Obstetric clinics: outcomes in 95 pregnancies at a tertiary centre over a 3-year period
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P434: Remission induction in corticosteroid naive children and adolescents with active ulcerative colitis by adsorptive leucocytapheresis after failure of first-line medications: Results from routine clinical practice
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P434: Surgery management of Crohn's disease in children: our experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P434: The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P434: Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn's disease: Results from induction and maintenance phase 3 trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM